CHOP is on the forefront of investigating the design and delivery of gene therapies to curb and potentially cure congenital diseases.

CHOP’s “Advancing Craniofacial Treatment with Genomics and Gene Therapy” Frontier Program is poised to harness genomic technologies to spearhead innovations in gene therapy, improve diagnostics, predict treatment outcomes and develop new therapies for children.

Our innovative fetal patient registry and data management system has made remarkable strides impacting both clinical care and research.

Expanded criteria for FETO procedure and transition to exclusively using muscle flap repair.

In its first year, our Newborn/Infant Intensive Care Unit at CHOP’s Middleman Family Pavilion in King of Prussia had over 250 admissions and expanded from 10 beds to 18.

Indepenema, a tool developed at CHOP, is a handheld device that allows patients with bowel incontinence to independently administer a cone enema, improving the process.

Urology, General Surgery and Gastroenterology (GI) at CHOP have teamed up to provide a better approach to care for patients with pediatric bladder and bowel dysfunction.

Two years ago, the Division of Urology established one of the country’s first percutaneous posterior tibial nerve stimulation pathways for pediatric bladder dysfunction.

Doctors from CHOP’s Division of Urology helped plan and present at the 2024 Joint Annual Fall Congress, the largest conference in the world dedicated to pediatric urology.

An experimental gene therapy, studied in a preclinical model of Batten disease, was found to slow symptoms and extend lifespan